Urologic cancers, which include prostate, bladder, and kidney malignancies, pose significant global health challenges due to ...

In April, 2025, Demis Hassabis, the Nobel Prize-winning CEO of Google DeepMind, appeared on the US television show 60 Minutes and suggested that all diseases could be curable with the help of ...

Trial data showed the drug dramatically reduced cancer progression risk in certain patients, supporting Celcuity’s plans to ...

From overlooked diagnostics and underused screening to AI potential and workforce gaps, these are the innovation challenges in oncology that cancer leaders told Becker’s they feel deserve more ...

Signals suggest the drugs could improve on the standard of care, but the market may not make it easy for another megablockbuster to rise to the top.

With Virgin shares holding nicely at cruising altitude, is now the right time for private oncology drug developer Qbiotics to ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

New capital, maturing pipelines, and a more global R&D mindset are pushing valuations higher, even as competition tightens.

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Pfizer is on the brink of a major rebound, transitioning focus to oncology and potential blockbuster drugs after a sharp drop in COVID-related revenues. Pfizer’s stock has plummeted over 50% in the ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

June was a slower month on the pharma agency side, but were several hires worth reporting, as well as a couple of interesting ...